Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586100 | 0.83 | KCNH2 (0.44) | ALDH1A3ALDH1A1ALDH3A1GAAHDAC1 | |
| SCHEMBL24219776 | 0.82 | HDAC1 (0.36) | ALDH1A3ALDH1A1ALDH3A1GAACYP2A6 | |
| SCHEMBL27139099 | 0.82 | HDAC1 (0.40) | ALDH1A1GAACYP2A6HDAC1HDAC2 | |
| SCHEMBL27148937 | 0.79 | HDAC1 (0.36) | ALDH1A3ALDH1A1GAACYP2A6HDAC1 | |
| SCHEMBL24085302 | 0.78 | MCHR1 (0.45) | ALDH1A1 | |
| SCHEMBL29935754 | 0.77 | CYP1A2 (0.57) | ALDH1A1GAACYP2A6 | |
| SCHEMBL31428581 | 0.77 | CYP1A2 (0.57) | ALDH1A1GAACYP2A6 | |
| SCHEMBL4587005 | 0.77 | CYP1A2 (0.57) | ALDH1A1GAACYP2A6 | |
| SCHEMBL30251515 | 0.76 | ALDH1A1 (0.42) | ALDH1A1GAAHDAC1HDAC2PDE10A | |
| SCHEMBL7833601 | 0.76 | NPC1 (0.39) | ALDH1A1GAAHDAC1HDAC2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | ALDH1A3 1902/4885ALDH1A1 4089/4885ALDH3A1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.